RecruitingPhase 1Phase 2NCT06906471
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Sponsor
Antelope Surgical Solutions, Inc
Enrollment
10 participants
Start Date
Jul 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 90 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called AS1986NS for people with fluorescence imaging, prostate cancer, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include men aged 18 Years to 90 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAS1986NS
Single dose, IV, 100 µg of AS1986NS
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06906471
Related Trials
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
NCT060968701 location
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT0685527788 locations
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT0654594218 locations
PSMA PET Combined With MRI for the Detection of PCa
NCT0705221418 locations
IDOV-Immune for Advanced Solid Tumors
NCT069106575 locations